Further studies on the structural requirements for mast cell degranulating (MCD) peptide-mediated histamine release

Area of Science:

• Immunology
• Biochemistry
• Peptide Chemistry

Background:

• Mast cell degranulating (MCD) peptide is a potent inducer of histamine release.
• Understanding the structural basis of MCD peptide's activity is crucial for developing targeted therapies.

Purpose of the Study:

• To investigate the role of disulfide bridges and arginine residues in MCD peptide's histamine-releasing activity.
• To synthesize and characterize MCD peptide analogs with modified disulfide bonds and arginine residues.

Main Methods:

• Synthesis of MCD peptide analogs: [Ala(3,15)]MCD, [Ala(5,19)]MCD, [Orn(16)]MCD, and [Orn(7,16)]MCD.
• In vitro histamine release assay using peritoneal mast cells.
• Spectrofluorometric determination of histamine release.
• Circular dichroism (CD) spectroscopy to analyze structural changes.

Main Results:

• Monocyclic analogs with alanine substitutions showed 3-10 fold decreased histamine-releasing activity.
• Ornithine substitutions for arginine residues significantly increased activity: ~6-fold for mono-substitution and 3-fold for di-substitution.
• CD spectroscopy revealed that disulfide bonds and arginine residues are critical for MCD peptide's conformation and biological function.

Conclusions:

• Disulfide bonds and arginine residues are essential for the potent histamine-releasing activity of MCD peptide.
• Modification of these residues can modulate the peptide's activity, offering potential for therapeutic applications.
• Structural insights from CD spectroscopy correlate with observed biological activities.